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Abstract 
Background: Targeted gene modification by homologous recombination provides a powerful tool for studying gene 
function in cells and animals. In higher eukaryotes, non-homologous integration of targeting vectors occurs several 
orders of magnitude more frequently than does targeted integration, making the gene-targeting technology highly 
inefficient. For this reason, negative-selection strategies have been employed to reduce the number of drug-resistant 
clones associated with non-homologous vector integration, particularly when artificial nucleases to introduce a DNA 
break at the target site are unavailable or undesirable. As such, an exon-trap strategy using a promoterless drug-resist-
ance marker gene provides an effective way to counterselect non-homologous integrants. However, constructing 
exon-trapping targeting vectors has been a time-consuming and complicated process.
Results: By virtue of highly efficient att-mediated recombination, we successfully developed a simple and rapid 
method to construct plasmid-based vectors that allow for exon-trapping gene targeting. These exon-trap vectors 
were useful in obtaining correctly targeted clones in mouse embryonic stem cells and human HT1080 cells. Most 
importantly, with the use of a conditionally cytotoxic gene, we further developed a novel strategy for negative selec-
tion, thereby enhancing the efficiency of counterselection for non-homologous integration of exon-trap vectors.
Conclusions: Our methods will greatly facilitate exon-trapping gene-targeting technologies in mammalian cells, 
particularly when combined with the novel negative selection strategy.
© 2015 Saito et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Gene targeting via homologous recombination provides 
a powerful means for studying gene function by a reverse 
genetic approach [1, 2]. This technology depends on 
homologous recombination reactions that occur between 
transfected DNA (i.e., targeting vector) and the host 
genome [3, 4]. In mammalian cells, however, this type of 
homologous recombination is quite a rare event. Even 
worse, targeting vectors integrate at overwhelmingly 
higher frequencies into random (or off-target) sites than 
into the target site [5], through non-homologous end-
joining (NHEJ) [6] and NHEJ-independent mechanisms 
[7, 8]. For these reasons, in addition to positive selection 
using a drug-resistance marker gene (which is franked 
with two homology arms), strategies termed negative 
selection have been preferentially used in mammalian 
cell gene targeting to reduce the number of drug-resist-
ant colonies associated with non-homologous vector 
integration into off-target sites [9].
To date, the most commonly used negative selection 
method is to place a counterselectable marker gene [e.g., 
a herpes simplex virus thymidine kinase gene or a gene 
coding for diphtheria toxin A fragment (DT-A)] outside 
of either (or both) of the homology arms. The presence 
of a toxic gene in the targeting vector is expected to kill 
random integrants (i.e., clones with off-target integration 
via non-homologous recombination), while having little 
impact on homologous recombination [10]. It appears, 
however, that this strategy has a limited efficacy of coun-
terselection (2–3-fold enrichment at the most) and is 
not routinely applicable to gene-targeting experiments 
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[11]. In fact, transient expression of DT-A is highly toxic 
to cells, resulting in a reduced colony formation rate 
after transfection. Another strategy to counterselect for 
non-homologous integration is to employ a promoter-
less drug-resistance gene as a positive-selection marker. 
In this case, the drug-resistance gene is only expressed 
functionally when fused, after vector integration into the 
host genome, to a coding sequence of expressed genes 
[12]. Although this strategy may not be applicable to 
genes with low expression levels, it has been reported 
that this type of targeting vectors is efficient in reduc-
ing the number of non-homologous integrants, without 
affecting absolute targeted integration frequencies [11]. 
More intriguingly, an exon-trap type of promoterless 
vectors has been shown to confer highly efficient gene 
targeting in mouse ES cells [13]. However, constructing 
such targeting vectors has been a time-consuming and 
complicated process, which typically involves the neces-
sity to search for appropriate restriction sites for ligation 
reactions or vector linearization. Therefore, the success 
of vector construction depends crucially on the skills of 
researchers. Moreover, although exon-trap vectors are 
expected to provide an efficient tool for gene targeting, 
this technology has yet to be fully explored and still has 
room for improvement.
In this paper, we describe a simple and rapid method 
to construct exon-trap vectors that allow for efficient 
targeted gene disruption in mouse and human cells. Fur-
thermore, we develop a novel method to enhance the 
efficiency of counterselection for non-homologous inte-
gration of exon-trap vectors. The combination of the 
rapid vector construction system and the novel negative 
selection strategy will greatly facilitate exon-trapping 
gene targeting in mammalian cells.
Methods
Vector construction
Oligonucleotides used to construct vectors are listed in 
Additional file  1: Table S1. All PCR reactions were per-
formed with ExTaqTM DNA polymerase (Takara Bio, 
Otsu, Japan) or KOD-Plus-DNA polymerase (Toyobo, 
Osaka, Japan). An entry clone plasmid, pENTR lox71-P, 
was constructed by inserting a 102-mer fragment con-
taining lox71, loxP and several restriction sites into NotI-
digested pENTR loxP plasmid [14]. The 102-mer DNA 
fragment was prepared by annealing oligonucleotides 
Lox71-P Fw and Lox71-P Rv (Additional file 1: Figure S1). 
The lox71 site is a mutant loxP site with 5 bp alterations 
[15].
To create entry clones for floxed promoterless mark-
ers, a hygromycin-resistance gene (HygR), a puromycin-
resistance gene (PuroR), a neomycin-resistance gene 
(NeoR), and a bifunctional lacZ/NeoR gene (βgeo) were 
each subcloned into pENTR lox71-P at the AscI and/or 
ClaI sites, with an IRES, IRES2 or 2A peptide sequence 
added upstream of each drug-resistance gene. The 
IRES sequence was derived from encephalomyocardi-
tis virus (ECMV) (Clontech, CA, USA; [16]). The IRES2 
sequence is identical to the IRES sequence, except for 
the absence of 22-bp deletion at the 5′ side (Clontech; 
[17]). The 2A peptide sequence was derived from Tho-
sea asigna virus (TaV) [18]. In this way, 12 entry clones 
(pENTR lox71P IRES-Hyg, pENTR lox71P IRES-Puro, 
pENTR lox71P IRES-Neo, pENTR lox71P IRES2-βgeo, 
pENTR lox71P IRES2-Hyg, pENTR lox71P IRES2-
Puro, pENTR lox71P 2A-βgeo, pENTR lox71P 2A-Hyg, 
pENTR lox71P 2A-Puro, pENTR lox71P 2A-EGFP-2A-
Puro, pENTR SA-IRES-Puro, and pENTR SA-IRES-Hyg) 
were constructed. Specifically, pENTR lox71P IRES-Hyg 
was constructed by subcloning a 2.2-kb XhoI/NgoMIV 
fragment containing IRES, HygR and polyA sequences 
into ClaI-digested pENTR lox71-P. pENTR lox71P 
IRES-Puro was constructed by subcloning a 1.3-kb 
MluI/PvuI fragment containing IRES, PuroR and polyA 
sequences into AscI/ClaI-digested pENTR lox71-P. 
pENTR lox71P IRES-Neo was constructed by subclon-
ing a 1.7-kb EcoRI/BamHI fragment containing IRES, 
NeoR and polyA sequences into ClaI-digested pENTR 
lox71-P. pENTR lox71P IRES2-βgeo was constructed 
with an In-Fusion®HD cloning kit (Clontech): a 4.7-kb 
fragment containing IRES2, βgeo and polyA sequences 
was PCR amplified with primers In-Fus Fw and In-Fus 
Rv, and the PCR fragment and ClaI-digested pENTR 
lox71-P were subjected to In-fusion cloning, yielding 
pENTR lox71P IRES2-βgeo. Likewise, pENTR lox71P 
IRES2-Hyg was constructed with In-Fusion®HD cloning 
kit (Clontech): a 1.9-kb fragment containing IRES2, HygR 
and polyA sequences was PCR amplified with primers In-
Fus Fw and In-Fus Rv, and the PCR fragment and ClaI-
digested pENTR lox71-P were subjected to In-fusion 
cloning, yielding pENTR lox71P IRES2-Ηyg. pENTR 
lox71P IRES2-Puro was constructed by subcloning a 
1.5-kb MluI/XhoI fragment containing IRES2, PuroR 
and polyA sequences into AscI/ClaI-digested pENTR 
lox71-P. pENTR lox71P 2A-βgeo was constructed by sub-
cloning a 4.3-kb AscI/AclI fragment containing 2A pep-
tide, βgeo and polyA sequences into AscI/ClaI-digested 
pENTR lox71-P. A 4.3-kb fragment containing 2A pep-
tide, βgeo and polyA sequences was PCR amplified 
with 2A-peptide sequence-containing primers (2AFw 
and 2ARv). pENTR lox71P 2A-Hyg was constructed by 
ligating a 1.1-kb BglII/NotI fragment containing HygR 
and a 3.1-kb BamHI/XbaI fragment containing 2A pep-
tide and polyA sequences derived from pENTR lox71P 
2A-βgeo. pENTR lox71P 2A-Puro was constructed by 
ligating a 0.6-kb BglII/EcoRV fragment containing PuroR 
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and a 3.1-kb BamHI/XbaI fragment containing the 2A 
peptide and polyA sequences. pENTR 2A-EGFP-2A-
Puro was constructed by ligating a 0.7-kb SmaI/SnaBI 
fragment containing 2A peptide and EGFP (Clontech; 
[19]) sequences and a 3.8-kb SmaI fragment containing 
2A peptide, PuroR and polyA sequences from pENTR 
lox71P 2A-Puro. pENTR SA-IRES-Puro was constructed 
by subcloning a 1.7-kb EcoRI/XhoI fragment contain-
ing SA (splice acceptor site; see below), IRES, PuroR and 
polyA sequences into EcoRI/SmaI-digested pENTR loxP. 
pENTR SA-IRES-Hyg was constructed by subcloning a 
2.6-kb EcoRV/PvuII fragment containing SA, IRES, HygR 
and polyA sequences into EcoRI/SmaI-digested pENTR 
loxP.
To generate targeting vectors for the human HPRT 
gene, 3.8 and 2.8-kb HPRT genomic fragments were 
PCR amplified with attB containing primers (HPRT-LH 
5′Fw and HPRT 5′Rv for the 3.8-kb 5′ arm and HPRT 
3′Fw and HPRT 3′Rv for the 2.8-kb 3′ arm). By using 
the MultiSite Gateway system (Life Technologies, Rock-
ville, MD, USA), a floxed HygR or PuroR gene was placed 
between the 5′ and 3′ arms, thus yielding targeting vec-
tors pHPRT-LH IRES2-Hyg and pHPRT-LH 2A-EGFP-
2A-Puro. Similarly, another HPRT targeting vector, 
pHPRT-SH 2A-EGFP-2A-Puro, was constructed using 
the MultiSite Gateway system to assemble two homol-
ogy arms (1.7 and 2.8-kb) and a drug-resistance gene cas-
sette. Genomic fragments for homology arms were PCR 
amplified with attB containing primers (HPRT-SH 5′Fw 
and HPRT 5′Rv for the 5′ arm and HPRT 3′Fw and HPRT 
3′Rv for the 3′ arm). All the plasmid vectors were purified 
with Qiagen Plasmid Plus Midi Kits (Qiagen K.K., Tokyo, 
Japan) and linearized with I-SceI (New England Biolabs, 
Ipswich, MA, USA) prior to transfection [20].
The mouse Rosa26 targeting vector, pmRosa26 IRES-
Puro, was constructed using the MultiSite Gateway sys-
tem. Briefly, 1.6 and 1.8-kb Rosa26 genomic fragments 
were obtained by PCR using mouse genomic DNA as 
template and were used as 5′ and 3′ arms, respectively. 
The primers containing attB sequences, mRosa26 5′Fw 
and mRosa26 5′Rv were used for the 5′ arm and mRosa26 
3′Fw and mRosa26 3′Rv for the 3′ arm. A PuroR gene was 
inserted between the 5′ and 3′ arms to yield pmRosa26 
IRES-Puro.
To construct a destination plasmid, pDEST SA–IRES–
DTA–pA, the ORF of a gene encoding diphtheria toxin A 
fragment (DT-A) was PCR amplified with primers con-
taining appropriate restriction sites for ligation reactions 
(DTA-Sal Fw and DTA-Not Rv) using pMC1DT-ApA 
plasmid (Kurabo, Osaka, Japan) as template. The PCR-
amplified cDNA products were subcloned into pGEM®-T 
Easy Vector (Promega, Madison, WI, USA). Meanwhile, 
a splice acceptor site (SA; a 174-bp BamHI fragment 
containing the adenovirus major late transcript splice 
acceptor sequence from the intron 1/exon 2 boundary) 
was excised from pSAβgeo [21]. The SA and DT-A frag-
ments were sequentially inserted into the NotI and XhoI 
sites of pIRES (Clontech), respectively. Subsequently, a 
1.8-kb BglII/PvuI fragment containing the SA–IRES–DT-
A–pA cassette was inserted into pDEST™R4-R3 (Life 
Technologies) at the AflIII site as illustrated in Additional 
file 1: Figure S2.
Cell culture and transfection
The human fibrosarcoma cell line HT1080 was obtained 
from Institution for Fermentation (Osaka, Japan). 
HT1080 cells were maintained at 37°C in ES medium 
(Nissui Seiyaku, Tokyo, Japan) supplemented with 10% 
heat-inactivated calf serum (growth medium) in a humid-
ified atmosphere of 5% CO2 in air. For passage, cells at 
late-log phase were washed once with Ca2+/Mg2+-free 
Phosphate-Buffered Saline (PBS–), and dispersed with 
0.1% trypsin/PBS− containing 0.02% EDTA for 5 min at 
37°C; the cells were collected by low-speed centrifuga-
tion, resuspended in fresh growth medium at an appro-
priate density, replated onto 60- or 90-mm tissue culture 
dishes (NUNC, Roskilde, Denmark), and cultured.
Undifferentiated embryonic stem cells, CGR8 [22], 
were maintained on gelatin-coated dishes in the 
absence of feeder cells in DMEM (Nacalai Tesque, 
Kyoto, Japan) supplemented with 15% KSR (Life Tech-
nologies, Rockville, MD, USA), 1% fetal bovine serum 
(Thermo Fisher Scientific, Waltham, MA, USA), 0.1 mM 
β-mercaptoethanol (Wako Pure Chemical, Osaka, Japan), 
1×MEM nonessential amino acids (Life Technologies) 
and LIF [22] at 37°C in a humidified atmosphere of 5% 
CO2 in air.
DNA transfection using the Nucleofector II system 
(Lonza, Basel, Switzerland) was performed according to 
the manufacturer’s instructions. Briefly, 2 × 106 cells were 
suspended with 100  μl of the supplied solutions (Solu-
tion T), and transfected with 2 μg of linearized targeting 
vector. The cells were cultured for 48 h and then replated 
at a density of 2–4 × 105 cells per 90-mm dish to deter-
mine the gene-targeting efficiency. Meanwhile, 1  ×  102 
cells were replated onto 60-mm dish to determine the 
plating efficiency. After a 24-h incubation, hygromycin B 
(0.25–0.4 mg/ml, Wako Pure Chemical, Osaka, Japan) or 
puromycin (0.4 or 0.5 μg/ml, Wako Pure Chemical) was 
added to the sample plates. After a 10–14-day incuba-
tion, the resulting drug-resistant colonies were isolated 
and expanded to prepare genomic DNA for PCR and 
Southern blot analysis. DNA transfection using the Max-
Cyte STX device (MaxCyte, Gaithersburg, MD, USA) 
was performed according to the manufacturer’s instruc-
tions. Briefly, 4 × 107 cells were suspended with 400 μl of 
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the supplied solutions (MaxCyte® Electroporation Buffer), 
and transfected with 40 μg of linearized targeting vector. 
Transfection into mouse ES cells was performed essen-
tially as described previously [23].
Gene targeting assay
The human HPRT targeting vector pHPRT-LH 2A-EGFP-
2A-Puro or pHPRT-SH 2A-EGFP-2A-Puro was trans-
fected into HT1080 cells, and puromycin-resistant 
colonies were counted to calculate the total integration 
frequency. Subsequently, single colonies were isolated 
and expanded to prepare genomic DNA. Gene-target-
ing events were screened by PCR analysis using primers 
HPRT-F and HPRT-R (Additional file  1: Table S1) and 
then confirmed by Southern blot analysis. The gene-
targeting efficiency was calculated by dividing the num-
ber of targeted clones with that of puromycin-resistant 
clones analyzed. The targeted integration frequency was 
calculated by multiplying the total integration frequency 
by the targeting efficiency. The random integration fre-
quency was calculated by subtracting the targeted inte-
gration frequency from the total integration frequency.
In mouse ES cells, gene-targeting assays were carried 
out essentially in the same manner as in HT1080 cells. 
Briefly, pmRosa26 IRES-Puro was linearized with I-SceI 
and transfected into mouse ES cells. After a 2–3  week 
incubation, genomic DNA was prepared from puromy-
cin-resistant clones and subjected to PCR analysis using 
primers mRosa26 5′ext and Universal primer C (Addi-
tional file 1: Table S1). The gene-targeting efficiency was 
calculated in the same manner as described above.
Southern blot analysis
Southern blotting was performed as described previ-
ously [23]. Briefly, 30 μg of genomic DNA was digested 
with EcoRV and StuI at 37°C and electrophoresed on 
a 0.8% agarose gel at 15  V for 14–18  h. Subsequently, 
DNA fragments were transferred to an Immobilon-Ny+ 
Transfer Membrane (Millipore, Concord Road, Billerica, 
MA, USA) by an alkaline transfer technique, followed by 
hybridization for >18  h at 55°C in hybridization buffer. 
The probe used was PCR amplified with primers HPRT 
3′probe Fw and HPRT 3′probe Rv (Additional file 1: Table 
S1). Southern hybridization was performed using Amer-
sham Gene Images AlkPhos Direct Labelling and Detec-
tion System (GE Healthcare Bio-Sciences, Piscataway, 
NJ, USA). Signals were detected with CDP-Star (Roche, 
Basel, Switzerland), and analyzed by using the Fuji Image 
Analyzer LAS-1000UVmini (Fuji Film Co., Tokyo, Japan).
Results
Rapid construction of exon‑trapping targeting vectors 
using att site‑mediated recombination
To develop a system that enables rapid construction of 
exon-trapping targeting vectors, we employed the com-
mercially available MultiSite Gateway® Technology. This 
technology enables one-step assembly of four DNA frag-
ments from different plasmids; namely, the backbone of a 
“destination vector” and three insert fragments subcloned 
in “entry clones”. Indeed, as we reported previously [14], 
the MultiSite Gateway system allowed us to rapidly con-
struct conventional targeting vectors harboring a pro-
moter-driven drug-resistance gene, which was originally 
subcloned in an entry clone plasmid. In this study, we 
first prepared a series of entry clones harboring a drug-
resistance gene (PuroR, HygR, NeoR or βgeo) flanked with 
lox71 and loxP sites (Figure 1a; Additional file 1: Figure 
S1). The use of floxed markers is of particular importance 
when one attempts to generate double- or triple-mutant 
cells, as a floxed region can be easily removed from the 
genome by transient expression of Cre recombinase in 
the cell. Importantly, the drug-resistance genes in these 
constructs do not possess a promoter; instead, an IRES 
or 2A peptide sequence is added upstream of each drug-
resistance gene. Thus, these promoterless drug-resist-
ance genes only acquire the ability to allow for positive 
selection when the ORF is fused to a coding sequence of 
expressed genes.
(See Figure on next page.)
Figure 1 A simple and efficient method to rapidly construct exon-trapping targeting vectors. a Schematic representation of entry clones with 
floxed promoterless markers. For simplicity, the plasmid backbone is not drawn. IRES internal ribosome entry site, 2A a 2A-peptide sequence 
derived from Thosea asigna virus (TaV), PuroR puromycin-resistance gene, HygR hygromycin-resistance gene, NeoR neomycin-resistance gene, βgeo 
lacZ/NeoR, EGFP enhanced green fluorescent protein gene, pA polyadenylation signal. Half-closed triangles and closed triangles represent lox71 and 
loxP sequences, respectively. b Primer design for PCR amplification of homology arms. Each primer has four guanine residues at the 5′ end followed 
by an attB sequence. The four attB sequences attB4, attB1, attB2 and attB3 differ from one another, enabling efficient site-specific BP and LR recom-
bination. The 5′-arm reverse primer should be set on the exon to be trapped (i.e., exon X in panel c), in order for the 5′-arm fragment to possess 
an authentic splice acceptor site at the 3′ side. The I-SceI site added to the 3′-arm reverse primer facilitates linearization of the resulting targeting 
vector. GSS gene-specific sequences. See text for details. c Flow diagram of construction of targeting vectors based on the MultiSite Gateway system, 
which consists of three steps: (1) PCR amplification with attB-containing primers, (2) BP recombination between 5′ or 3′ arm fragment and a donor 
vector (pDONR P4-P1R or pDONR P2R-P3, respectively), and (3) LR recombination to yield the targeting vector by one-time assembly of four DNA 
fragments (see text for details). SA splice acceptor site, drugR drug-resistance gene, KmR kanamycin-resistance gene, AmpR ampicillin-resistance gene. 
d Schematic representation of pENTR SA-IRES-Puro and pENTR SA-IRES-Hyg. These two entry clones harbor an SA site-linked promoterless marker 
gene. See “Methods” for details.
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We next PCR amplified 5′ and 3′ homology arms 
by using four attB-containing primers. For these PCR 
reactions, the reverse primer for 5′-arm amplification 
should be set on an exon to be trapped (or disrupted), 
as depicted in Figure 1b. In this way, an authentic splice 
acceptor (SA) site is naturally incorporated at the 3′ side 
of the 5′-arm fragment. Also, the reverse primer for 
3′-arm amplification contains an I-SceI site (Figure 1b). 
This I-SceI site permits linearization of the resultant tar-
geting vector, without the need for extensive restriction 
mapping. The amplified fragments were then subjected 
to BP recombination to yield 5′ and 3′ arm-containing 
entry clones (Figure  1c). Finally, the three entry clones 
and the destination vector pDEST™R4-R3 were sub-
jected to LR recombination to assemble the 5′ arm, an 
IRES/2A-linked drug-resistance gene, and the 3′ arm 
together, thus yielding the exon-trapping targeting vec-
tor (Figure 1c).
Using the method described above, we constructed 
several targeting vectors for the mouse Rosa26 gene and 
the human HPRT gene (Additional file  1: Figure S3). 
Importantly, we were able to construct these vectors 
shorter than 10 days, usually within 1 week. In addition, 
the two subcloning steps using BP and LR recombination 
were quite efficient, with little or no appearance of E. coli 
transformants harboring incorrect plasmids.
In general, designing a primer on an exonic sequence is 
easy and beneficial in performing an efficient and highly 
specific PCR reaction, given that exonic sequences tend 
to be more unique than are intronic sequences, which 
are rich in repetitive DNA sequences. In some cases, 
however, one may favor to set the 5′-arm reverse primer 
(i.e., the 3′ end of the 5′ arm) on an intronic sequence. 
We therefore constructed additional entry clones, in 
which a drug-resistance gene cassette possesses an SA 
site upstream of the IRES sequence (Figure  1d; pENTR 
SA-IRES-Puro and pENTR SA-IRES-Hyg). These entry 
clones will be useful for constructing a targeting vector 
that is designed to trap an intronic region of the target 
gene.
Exon‑trapping gene targeting in mouse ES cells 
and human HT1080 cells
To evaluate the usefulness of exon-trap vectors for actual 
gene-targeting experiments, we examined whether the 
Rosa26 targeting vector described above was competent 
for gene disruption in mouse ES cells. Electroporation 
of I-SceI-linearized pmRosa26 IRES-Puro into mouse ES 
cells (1.3  ×  107 cells) gave rise to 13 puromycin-resist-
ant clones, and 2 clones were found to be correctly tar-
geted. Thus, the targeting efficiency was considerably 
high (15.4%), even though the targeting vector contained 
relatively short homology arms (1.6 and 1.8 kb). We next 
employed a human cell line, HT1080, to evaluate HPRT 
targeting vectors. The HT1080 cell line has a near-diploid 
karyotype [24] and has been frequently used for studies 
on gene targeting [25–27]. Using a MaxCyte electropo-
ration system, I-SceI-linearized pHPRT-SH 2A-EGFP-
2A-Puro was transfected into HT1080 cells. As shown in 
Table 1, the HPRT gene was successfully knocked out in 
these cells.
ExTraPANS: a novel negative selection cassette 
that efficiently counterselects for non‑homologous 
integration into off‑target genomic sites
In the experiments described above, exon-trap vectors 
were successfully utilized to disrupt mammalian genes in 
a desired manner. In human somatic cells, however, the 
targeting efficiency was not as high as expected, owing 
to the occurrence of a large number of drug-resistant 
colonies associated with non-homologous integration 
of exon-trap vectors into off-target sites. We therefore 
sought to examine whether exon-trap-based gene tar-
geting could be further enhanced when combined with 
an additional strategy. For this aim, we designed a novel 
negative selection cassette composed of a promoterless 
toxic gene, as shown in Figure  2a. In this cassette, the 
DT-A gene does not have a promoter and, therefore, is 
not expressed in a transient manner; instead, an SA site 
and an IRES sequence are added upstream of the DT-A 
gene in a manner similar to promoterless drug-resistance 
genes for positive selection. We anticipated that when 
this cassette is placed upstream of the 5′ arm of an exon-
trapping targeting vector, non-homologous integrants 
that are otherwise capable of acquiring drug resistance 
would express the DT-A gene and thus fail to form viable 
colonies, as depicted in Figure  2b. In contrast, targeted 
integration via homologous recombination would not be 
affected.
We next inserted this cassette (i.e., SA–IRES–DT-
A–polyA sequence) into the destination vector 
pDEST™R4-R3 (near the attR4 site), and named the 
Table 1 Exon-trap-based HPRT-gene targeting in  HT1080 
cells
The targeting vector pHPRT-SH 2A-EGFP-2A-Puro was I-SceI linearized and 
transfected into HT1080 cells, and the gene-targeting efficiency was determined 
as described in “Methods”.
Experiment Number of cells 
transfected
Total number 
of puromycin‑
resistant colonies
Gene‑targeting 
efficiency
1 4.0 × 107 411 0.8% (2/244)
2 4.0 × 107 614 0.4% (2/501)
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resulting plasmid pDEST SA–IRES–DTA–pA (Additional 
file  1: Figure S2). We then constructed targeting vectors 
for the mouse Rosa26 and human HPRT genes in the 
same manner as described above, except that pDEST SA–
IRES–DTA–pA was employed instead of pDEST™R4-R3. 
When these targeting vectors were transfected into 
HT1080 cells, a significant reduction in the number of 
drug-resistant clones was observed. As shown in Table 2, 
the absolute integration frequency was decreased ~5–25-
fold when the negative selection cassette was present 
in the targeting vector. More importantly, by virtue of 
reduced integration frequencies, the targeting efficiency 
was actually enhanced when the targeting vector pos-
sessed the negative selection cassette (Table  3; Experi-
ments 1–3). We further employed mouse ES cells and 
found that the targeting efficiency at the Rosa26 locus 
was enhanced by the presence of the negative selection 
cassette in the targeting vector (Table  3; Experiment 4). 
These results demonstrate that the novel negative selec-
tion cassette with a conditionally cytotoxic DT-A gene 
is indeed effective in further reducing the number of 
non-homologous off-target integrants. We termed this 
novel strategy “ExTraPANS”, which stands for exon-trap-
ping positive and negative selection.
a
b
Figure 2 Schematic representation of the novel negative selection strategy. a Schematic representation of a conditionally cytotoxic gene cassette 
composed of an SA site, an IRES sequence, a DT-A gene and a polyA sequence. This cassette, when placed upstream of the 5′ arm of an exon-trap-
ping targeting vector, is expected to function as a negative selection marker. b Schematic representation of the impact of the negative selection 
cassette on integration events. When an exon-trap vector integrates non-homologously into a gene-coding region, the cells are capable of acquir-
ing drug resistance (i, left panel). In contrast, when an exon-trap vector possesses the negative selection cassette (ExTraPANS vector), the upstream 
SA site would trap the splicing from the upstream exon (grey box) to allow DT-A gene expression, thereby killing random integrants (i, right panel). 
On the other hand, the presence of the negative selection cassette is expected not to affect homologous recombination-mediated targeted inte-
gration (ii). Abbreviations are as in Figure 1.
Table 2 Effect of  the novel negative selection cassette 
on integration frequency
The targeting vector pHPRT-SH 2A-EGFP-2A-Puro was I-SceI linearized and 
transfected into HT1080 cells by using the Nucleofector II system (Experiments 
1 and 2) or the MaxCyte devise (Experiment 3). DT-A denotes the presence (+) 
or absence (−) of the ExTraPANS cassette (SA–IRES–DT-A–polyA sequence) in 
the targeting vector. The random-integration frequency was determined as 
described in “Methods”.
a Numbers in parentheses represent relative random-integration frequencies.
Experiment DT‑A Random integration 
frequencya
Fold 
decrease
1 − 1.0 × 10−4 (1) 25
+ 4.1 × 10−6 (0.04)
2 − 2.8 × 10−5 (1) 8.5
+ 3.3 × 10−6 (0.12)
3 − 6.2 × 10−5 (1) 5.6
+ 1.1 × 10−5 (0.18)
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Discussion
In this paper, we have established a simple and rapid 
method to construct exon-trap vectors that enable to dis-
rupt virtually any locus of expressed genes of interest in a 
desired manner. Our vector construction system is sim-
pler and quicker than any other methods reported thus 
far. Furthermore, we have developed a novel strategy for 
negative selection to enhance gene targeting by virtue of 
dramatically reduced random-integration frequencies. 
Since the negative selection cassette (SA–IRES–DT-
A–polyA) has been placed in a ready-to-use destination 
vector (pDEST SA–IRES–DTA–pA), rapid construction 
of exon-trap vectors harboring this cassette can be eas-
ily performed using the MultiSite Gateway® Technology, 
usually within 1 week. Thus, our strategy described here 
is usefully applicable to gene-knockout/knock-in experi-
ments in human somatic cells as well as mouse ES cells.
In somatic cell gene-knockout experiments, multi-
ple marker gene cassettes are needed for the purpose of 
disrupting more than one locus [14]. Thus, we have con-
structed a series of floxed promoterless marker genes that 
allow for positive selection with puromycin, hygromycin, 
or neomycin (G418). Indeed, we have confirmed that all 
of these cassettes are competent as a positive selection 
marker in human somatic cells (our unpublished obser-
vations). Previous work has suggested that although an 
exon-trap type of targeting vectors is useful for mam-
malian cell gene targeting, the efficiency likely depends 
on cellular expression levels of the target gene [21]. For 
this reason, we employed a 2A peptide sequence as well 
as an IRES (or IRES2) sequence for each of the selection 
markers. The IRES/IRES2 sequences allow expression 
of multiple ORFs from the same mRNA, with weaker 
expression of a downstream gene(s). In contrast, 2A pep-
tide sequences allow expression of multiple genes on a 
single ORF at the same level [28]. We therefore expected 
that 2A peptide-linked drug-resistance genes might be 
three-times more effective in reducing random inte-
grants than IRES-linked markers, because the 2A peptide 
sequence must be fused in-frame to a coding sequence of 
expressed non-target genes in order for cells to acquire 
drug resistance. However, a significant number of ran-
dom integrants were actually observed with a 2A-linked 
drug-resistance gene, while we were able to obtain cor-
rectly targeted clones with satisfactory efficiencies. We 
speculate that 2A peptide sequences could have more 
chance than IRES sequences to confer drug resistance 
when non-homologously integrated into genes with low 
expression levels.
Accumulating evidence indicates that the targeting effi-
ciency is stimulated by a DNA break introduced at the 
chromosomal target site [29–31]. In particular, recently 
developed methods using artificial nucleases such as 
ZFN, TALEN or CRISPR have been dramatically improv-
ing genome-engineering technologies [32–34]. It is worth 
noting, however, that such nuclease-triggered gene tar-
geting is capable of causing mutations owing to unex-
pected off-target effects [35–37]. For this reason, using 
artificial nucleases may not be desirable or should be 
avoided in some cases. We therefore refocused on sim-
pler strategies that could be combined with exon-trap-
ping targeting vectors, and have succeeded in developing 
a novel strategy termed ExTraPANS that can even more 
efficiently counterselect for random integration events. 
With the use of the ExTraPANS strategy, we have shown 
that the targeting efficiency can be elevated to as high 
as ~4.7% in human HT1080 cells. Yet, there is still room 
for improvement. In fact, although we had expected that 
random-integration frequencies might drop to zero with 
the ExTraPANS strategy, we actually encountered an 
unignorable number of random integrants. Two possi-
bilities may explain the imperfect efficacy of our current 
strategy. One possibility is that, prior to or during the 
non-homologous integration event, the targeting vector 
has been nucleolytically degraded to lose (at least part of ) 
the negative-selection cassette sequence, thereby disa-
bling DT-A expression. In support of this view, frequent 
terminal deletions have been observed with chromosom-
ally integrated plasmid vectors in mouse ES cells [38] and 
in human somatic cells (our unpublished observations). 
Another possibility is that, even when the negative selec-
tion cassette remained intact after integration, the SA 
sequence we employed could not work efficiently at cer-
tain loci and thus DT-A was not fully expressed to exert 
cytotoxicity. Such functional inertness of ectopic SA sites 
in the genome has been reported earlier in experiments 
using exon-trap vectors [39]. Since our preliminary 
experiments suggest that these two possibilities both 
Table 3 Effect of  the novel negative selection cassette 
on targeting efficiency
Human HT1080 cells and mouse ES cells were used for targeted disruption of the 
HPRT locus (Experiments 1–3) or the Rosa26 locus (Experiment 4), respectively. 
DT-A denotes the presence (+) or absence (−) of the ExTraPANS cassette (SA–
IRES–DT-A–polyA sequence) in the targeting vector.
Experiment Selection markerDT‑A Gene‑targeting 
efficiency
Fold increase
1 2A-EGFP-2A-Puro − 0.4% (1/250) 9.0
+ 3.6% (2/55)
2 2A-Puro − 1.7% (2/116) 2.8
+ 4.7% (2/43)
3 IRES2-Hyg − 0% (0/133) >4.6
+ 3.7% (1/27)
4 IRES-Puro − 0% (0/7) >3.5
+ 50% (1/2)
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seem likely, we are currently trying to overcome these 
issues to further enhance the efficacy of the ExTraPANS 
strategy.
Conclusions
In summary, we have established an efficient method 
to perform exon-trap-based gene targeting in mamma-
lian cells. The novel strategy using a promoterless DT-A 
gene has the capacity to significantly reduce the num-
ber of off-target integrants. Although the efficiency of 
exon-trapping gene targeting may largely be influenced 
by the expression level of the target gene, the usefulness 
of the ExTraPANS strategy is quite intriguing and must 
be emphasized. Our methods described here will greatly 
facilitate gene-knockout/knock-in experiments in mam-
malian cells.
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